Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation.

Gu Z, Liu Y, Cai F, Patrick M, Zmajkovic J, Cao H, Zhang Y, Tasdogan A, Chen M, Qi L, Liu X, Li K, Lyu J, Dickerson KE, Chen W, Ni M, Merritt ME, Morrison SJ, Skoda RC, DeBerardinis RJ, Xu J.

Cancer Discov. 2019 Jun 12. pii: CD-19-0152. doi: 10.1158/2159-8290.CD-19-0152. [Epub ahead of print]

PMID:
31189531
2.

Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans.

Kaasinen E, Kuismin O, Rajamäki K, Ristolainen H, Aavikko M, Kondelin J, Saarinen S, Berta DG, Katainen R, Hirvonen EAM, Karhu A, Taira A, Tanskanen T, Alkodsi A, Taipale M, Morgunova E, Franssila K, Lehtonen R, Mäkinen M, Aittomäki K, Palotie A, Kurki MI, Pietiläinen O, Hilpert M, Saarentaus E, Niinimäki J, Junttila J, Kaikkonen K, Vahteristo P, Skoda RC, Seppänen MRJ, Eklund KK, Taipale J, Kilpivaara O, Aaltonen LA.

Nat Commun. 2019 Mar 19;10(1):1252. doi: 10.1038/s41467-019-09198-7.

3.

Dual roles of EZH2 in acute myeloid leukemia.

Skoda RC, Schwaller J.

J Exp Med. 2019 Apr 1;216(4):725-727. doi: 10.1084/jem.20190250. Epub 2019 Mar 19.

PMID:
30890555
4.

Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.

Stivala S, Codilupi T, Brkic S, Baerenwaldt A, Ghosh N, Hao-Shen H, Dirnhofer S, Dettmer MS, Simillion C, Kaufmann BA, Chiu S, Keller M, Kleppe M, Hilpert M, Buser AS, Passweg JR, Radimerski T, Skoda RC, Levine RL, Meyer SC.

J Clin Invest. 2019 Mar 4;130:1596-1611. doi: 10.1172/JCI98785. eCollection 2019 Mar 4.

5.

Accelerating myelofibrosis through loss of Dnmt3a.

Skoda RC.

Blood. 2018 Dec 27;132(26):2703-2704. doi: 10.1182/blood-2018-11-883470. No abstract available.

PMID:
30591541
6.

The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14.

Drexler B, Passweg JR, Tzankov A, Bigler M, Theocharides AP, Cantoni N, Keller P, Stussi G, Ruefer A, Benz R, Favre G, Lundberg P, Nienhold R, Fuhrer A, Biaggi C, Manz MG, Bargetzi M, Mendez-Ferrer S, Skoda RC; Swiss Group for Clinical Cancer Research (SAKK).

Haematologica. 2019 Apr;104(4):710-716. doi: 10.3324/haematol.2018.200014. Epub 2018 Nov 8.

7.

A Gain-of-Function Mutation in EPO in Familial Erythrocytosis.

Zmajkovic J, Lundberg P, Nienhold R, Torgersen ML, Sundan A, Waage A, Skoda RC.

N Engl J Med. 2018 Mar 8;378(10):924-930. doi: 10.1056/NEJMoa1709064.

8.

Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.

Nieborowska-Skorska M, Maifrede S, Dasgupta Y, Sullivan K, Flis S, Le BV, Solecka M, Belyaeva EA, Kubovcakova L, Nawrocki M, Kirschner M, Zhao H, Prchal JT, Piwocka K, Moliterno AR, Wasik M, Koschmieder S, Green TR, Skoda RC, Skorski T.

Blood. 2017 Dec 28;130(26):2848-2859. doi: 10.1182/blood-2017-05-784942. Epub 2017 Oct 17.

9.

Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera.

Meyer SC, Steinmann E, Lehmann T, Muesser P, Passweg JR, Skoda RC, Tsakiris DA.

Biomed Res Int. 2017;2017:9876819. doi: 10.1155/2017/9876819. Epub 2017 Jun 18.

10.

Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants.

Pastor V, Hirabayashi S, Karow A, Wehrle J, Kozyra EJ, Nienhold R, Ruzaike G, Lebrecht D, Yoshimi A, Niewisch M, Ripperger T, Göhring G, Baumann I, Schwarz S, Strahm B, Flotho C, Skoda RC, Niemeyer CM, Wlodarski MW.

Leukemia. 2017 Mar;31(3):759-762. doi: 10.1038/leu.2016.342. Epub 2016 Nov 23. No abstract available.

PMID:
27876779
11.

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.

Shimizu T, Kubovcakova L, Nienhold R, Zmajkovic J, Meyer SC, Hao-Shen H, Geier F, Dirnhofer S, Guglielmelli P, Vannucchi AM, Feenstra JD, Kralovics R, Orkin SH, Skoda RC.

J Exp Med. 2016 Jul 25;213(8):1479-96. doi: 10.1084/jem.20151136. Epub 2016 Jul 11.

12.

Angiogenic factors are increased in circulating granulocytes and CD34+ cells of myeloproliferative neoplasms.

Subotički T, Mitrović Ajtić O, Beleslin-Čokić BB, Nienhold R, Diklić M, Djikić D, Leković D, Bulat T, Marković D, Gotić M, Noguchi CT, Schechter AN, Skoda RC, Čokić VP.

Mol Carcinog. 2017 Feb;56(2):567-579. doi: 10.1002/mc.22517. Epub 2016 Jul 8.

PMID:
27341002
13.

JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis.

Grisouard J, Li S, Kubovcakova L, Rao TN, Meyer SC, Lundberg P, Hao-Shen H, Romanet V, Murakami M, Radimerski T, Dirnhofer S, Skoda RC.

Blood. 2016 Aug 11;128(6):839-51. doi: 10.1182/blood-2015-12-689216. Epub 2016 Jun 10.

14.

Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency.

Theocharides AP, Lundberg P, Lakkaraju AK, Lysenko V, Myburgh R, Aguzzi A, Skoda RC, Manz MG.

Blood. 2016 Jun 23;127(25):3253-9. doi: 10.1182/blood-2016-02-696310. Epub 2016 Mar 24.

15.

Mutational profile of childhood myeloproliferative neoplasms.

Karow A, Nienhold R, Lundberg P, Peroni E, Putti MC, Randi ML, Skoda RC.

Leukemia. 2015 Dec;29(12):2407-9. doi: 10.1038/leu.2015.205. Epub 2015 Jul 30. No abstract available.

PMID:
26223499
16.

Pathogenesis of myeloproliferative neoplasms.

Skoda RC, Duek A, Grisouard J.

Exp Hematol. 2015 Aug;43(8):599-608. doi: 10.1016/j.exphem.2015.06.007. Epub 2015 Jul 21. Review.

17.

ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.

Hammarén HM, Ungureanu D, Grisouard J, Skoda RC, Hubbard SR, Silvennoinen O.

Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4642-7. doi: 10.1073/pnas.1423201112. Epub 2015 Mar 30.

18.

Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN.

Grisouard J, Shimizu T, Duek A, Kubovcakova L, Hao-Shen H, Dirnhofer S, Skoda RC.

Blood. 2015 Mar 26;125(13):2131-40. doi: 10.1182/blood-2014-08-594572. Epub 2015 Jan 16.

19.

Estrogen signaling selectively induces apoptosis of hematopoietic progenitors and myeloid neoplasms without harming steady-state hematopoiesis.

Sánchez-Aguilera A, Arranz L, Martín-Pérez D, García-García A, Stavropoulou V, Kubovcakova L, Isern J, Martín-Salamanca S, Langa X, Skoda RC, Schwaller J, Méndez-Ferrer S.

Cell Stem Cell. 2014 Dec 4;15(6):791-804. doi: 10.1016/j.stem.2014.11.002.

20.

Haemorrhagic and thrombotic diatheses in mouse models with thrombocytosis.

Strassel C, Kubovcakova L, Mangin PH, Ravanat C, Freund M, Skoda RC, Denis CV, Dupuis A, Herbrecht R, Gachet C, Lanza F.

Thromb Haemost. 2015 Feb;113(2):414-25. doi: 10.1160/TH14-08-0667. Epub 2014 Oct 9.

PMID:
25298269
21.

Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F.

Lundberg P, Takizawa H, Kubovcakova L, Guo G, Hao-Shen H, Dirnhofer S, Orkin SH, Manz MG, Skoda RC.

J Exp Med. 2014 Oct 20;211(11):2213-30. doi: 10.1084/jem.20131371. Epub 2014 Oct 6.

22.

Less Jak2 makes more platelets.

Skoda RC.

Blood. 2014 Oct 2;124(14):2168-9. doi: 10.1182/blood-2014-08-596361. No abstract available.

23.

Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two-photon imaging.

Santisakultarm TP, Paduano CQ, Stokol T, Southard TL, Nishimura N, Skoda RC, Olbricht WL, Schafer AI, Silver RT, Schaffer CB.

J Thromb Haemost. 2014 Dec;12(12):2120-30. doi: 10.1111/jth.12738. Epub 2014 Oct 29.

24.

Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms.

Arranz L, Sánchez-Aguilera A, Martín-Pérez D, Isern J, Langa X, Tzankov A, Lundberg P, Muntión S, Tzeng YS, Lai DM, Schwaller J, Skoda RC, Méndez-Ferrer S.

Nature. 2014 Aug 7;512(7512):78-81. doi: 10.1038/nature13383. Epub 2014 Jun 22.

PMID:
25043017
25.

Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs.

Duek A, Lundberg P, Shimizu T, Grisouard J, Karow A, Kubovcakova L, Hao-Shen H, Dirnhofer S, Skoda RC.

Blood. 2014 Jun 19;123(25):3943-50. doi: 10.1182/blood-2013-07-514208. Epub 2014 May 12.

26.

Somatic mutations in calreticulin can be found in pedigrees with familial predisposition to myeloproliferative neoplasms.

Lundberg P, Nienhold R, Ambrosetti A, Cervantes F, Pérez-Encinas MM, Skoda RC.

Blood. 2014 Apr 24;123(17):2744-5. doi: 10.1182/blood-2014-01-550863. No abstract available.

27.

Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia.

Grisouard J, Hao-Shen H, Dirnhofer S, Wagner KU, Skoda RC.

Haematologica. 2014 Apr;99(4):e52-4. doi: 10.3324/haematol.2013.100016. Epub 2014 Feb 7. No abstract available.

28.

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.

Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, Girsberger S, Lehmann T, Passweg J, Stern M, Beisel C, Kralovics R, Skoda RC.

Blood. 2014 Apr 3;123(14):2220-8. doi: 10.1182/blood-2013-11-537167. Epub 2014 Jan 29.

29.

Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia.

Grisouard J, Ojeda-Uribe M, Looser R, Hao-Shen H, Lundberg P, Duek A, Jeandidier E, Karow A, Skoda RC.

Blood. 2013 Nov 21;122(22):3694-6. doi: 10.1182/blood-2013-07-516385. No abstract available.

30.

Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model.

Kubovcakova L, Lundberg P, Grisouard J, Hao-Shen H, Romanet V, Andraos R, Murakami M, Dirnhofer S, Wagner KU, Radimerski T, Skoda RC.

Blood. 2013 Feb 14;121(7):1188-99. doi: 10.1182/blood-2012-03-415646. Epub 2012 Dec 20.

31.

Raising hematology's European voice: the importance of calling yourself a hematologist.

de Wit TD, Borkhardt A, Chomienne C, Döhner H, Fibbe WE, Foà R, Hagenbeek A, Skoda RC, Smand CR, Jäger U.

Haematologica. 2012 Apr;97(4):476-8. doi: 10.3324/haematol.2011.057257. No abstract available.

32.

The DEAH-box helicase RHAU is an essential gene and critical for mouse hematopoiesis.

Lai JC, Ponti S, Pan D, Kohler H, Skoda RC, Matthias P, Nagamine Y.

Blood. 2012 May 3;119(18):4291-300. doi: 10.1182/blood-2011-08-362954. Epub 2012 Mar 15.

33.

The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling.

Ungureanu D, Wu J, Pekkala T, Niranjan Y, Young C, Jensen ON, Xu CF, Neubert TA, Skoda RC, Hubbard SR, Silvennoinen O.

Nat Struct Mol Biol. 2011 Aug 14;18(9):971-6. doi: 10.1038/nsmb.2099.

34.

Biphasic roles for soluble guanylyl cyclase (sGC) in platelet activation.

Zhang G, Xiang B, Dong A, Skoda RC, Daugherty A, Smyth SS, Du X, Li Z.

Blood. 2011 Sep 29;118(13):3670-9. doi: 10.1182/blood-2011-03-341107. Epub 2011 Jul 29.

35.

SCL-mediated regulation of the cell-cycle regulator p21 is critical for murine megakaryopoiesis.

Chagraoui H, Kassouf M, Banerjee S, Goardon N, Clark K, Atzberger A, Pearce AC, Skoda RC, Ferguson DJ, Watson SP, Vyas P, Porcher C.

Blood. 2011 Jul 21;118(3):723-35. doi: 10.1182/blood-2011-01-328765. Epub 2011 May 19.

36.

HiJAKing the methylosome in myeloproliferative disorders.

Skoda RC, Schwaller J.

Cancer Cell. 2011 Feb 15;19(2):161-3. doi: 10.1016/j.ccr.2011.01.046.

37.

Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2.

Schaub FX, Lehmann T, Looser R, Hao-Shen H, Tichelli A, Skoda RC.

Blood. 2011 Feb 10;117(6):2075-6. doi: 10.1182/blood-2010-11-316471. No abstract available.

38.

Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.

Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR, Girodon F, Kiladjian JJ, McMullin MF, Ruggeri M, Besses C, Vannucchi AM, Lippert E, Gisslinger H, Rumi E, Lehmann T, Ortmann CA, Pietra D, Pascutto C, Haferlach T, Cazzola M.

Blood. 2011 Mar 10;117(10):2813-6. doi: 10.1182/blood-2010-11-316810. Epub 2011 Jan 11.

39.

Hereditary thrombocytosis not as innocent as thought? Development into acute leukemia and myelofibrosis.

Posthuma HL, Skoda RC, Jacob FA, van der Maas AP, Valk PJ, Posthuma EF.

Blood. 2010 Oct 28;116(17):3375-6. doi: 10.1182/blood-2010-06-290718. No abstract available.

40.

JAK2 impairs stem cell function?

Skoda RC.

Blood. 2010 Sep 2;116(9):1392-3. doi: 10.1182/blood-2010-06-287318. No abstract available.

41.

Hereditary myeloproliferative disorders.

Skoda RC.

Haematologica. 2010 Jan;95(1):6-8. doi: 10.3324/haematol.2009.015941. No abstract available.

42.

Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.

Schaub FX, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A, Skoda RC.

Blood. 2010 Mar 11;115(10):2003-7. doi: 10.1182/blood-2009-09-245381. Epub 2010 Jan 8.

43.

Thrombocytosis.

Skoda RC.

Hematology Am Soc Hematol Educ Program. 2009:159-67. doi: 10.1182/asheducation-2009.1.159. Review.

PMID:
20008195
44.

Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia.

Liu K, Martini M, Rocca B, Amos CI, Teofili L, Giona F, Ding J, Komatsu H, Larocca LM, Skoda RC.

Haematologica. 2009 Oct;94(10):1368-74. doi: 10.3324/haematol.2009.005918. Epub 2009 Jul 16.

45.

The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera.

Olcaydu D, Skoda RC, Looser R, Li S, Cazzola M, Pietra D, Passamonti F, Lippert E, Carillo S, Girodon F, Vannucchi A, Reading NS, Prchal JT, Ay C, Pabinger I, Gisslinger H, Kralovics R.

Leukemia. 2009 Oct;23(10):1924-6. doi: 10.1038/leu.2009.110. Epub 2009 May 14. No abstract available.

PMID:
19440215
46.

Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F.

Schaub FX, Jäger R, Looser R, Hao-Shen H, Hermouet S, Girodon F, Tichelli A, Gisslinger H, Kralovics R, Skoda RC.

Blood. 2009 Feb 26;113(9):2022-7. doi: 10.1182/blood-2008-07-167056. Epub 2008 Dec 1.

47.

Concordance of assays designed for the quantification of JAK2V617F: a multicenter study.

Lippert E, Girodon F, Hammond E, Jelinek J, Reading NS, Fehse B, Hanlon K, Hermans M, Richard C, Swierczek S, Ugo V, Carillo S, Harrivel V, Marzac C, Pietra D, Sobas M, Mounier M, Migeon M, Ellard S, Kröger N, Herrmann R, Prchal JT, Skoda RC, Hermouet S.

Haematologica. 2009 Jan;94(1):38-45. doi: 10.3324/haematol.13486. Epub 2008 Nov 10.

48.

Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes.

Tiedt R, Coers J, Ziegler S, Wiestner A, Hao-Shen H, Bornmann C, Schenkel J, Karakhanova S, de Sauvage FJ, Jackson CW, Skoda RC.

Blood. 2009 Feb 19;113(8):1768-77. doi: 10.1182/blood-2008-03-146084. Epub 2008 Oct 9.

49.

The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders.

Theocharides A, Passweg JR, Medinger M, Looser R, Li S, Hao-Shen H, Buser AS, Gratwohl A, Tichelli A, Skoda RC.

Haematologica. 2008 Dec;93(12):1890-3. doi: 10.3324/haematol.13074. Epub 2008 Sep 11.

50.

Can we control JAK?

Skoda RC.

Blood. 2008 Jun 15;111(12):5419-20. doi: 10.1182/blood-2007-11-123810. No abstract available.

Supplemental Content

Loading ...
Support Center